

Alexander Kiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3589924/publications.pdf>

Version: 2024-02-01

64
papers

4,359
citations

257357

24
h-index

161767

54
g-index

65
all docs

65
docs citations

65
times ranked

6159
citing authors

#	ARTICLE	IF	CITATIONS
1	Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE (AIO KKR0306). <i>International Journal of Cancer</i> , 2022, 150, 112-123.	2.3	10
2	UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. <i>Leukemia</i> , 2022, 36, 1676-1680.	3.3	12
3	Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3. <i>British Journal of Cancer</i> , 2022, 127, 836-843.	2.9	5
4	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. <i>British Journal of Cancer</i> , 2021, 124, 587-594.	2.9	79
5	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	3.3	40
6	Preinfection laboratory parameters may predict COVID-19 severity in tumor patients. <i>Cancer Medicine</i> , 2021, 10, 4424-4436.	1.3	3
7	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KKR 0306; FIRE). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	2.3	3
8	Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response. <i>Blood</i> , 2021, 138, 3608-3608.	0.6	3
9	Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results. <i>Blood</i> , 2021, 138, 635-635.	0.6	2
10	Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. <i>Acta Haematologica</i> , 2020, 143, 217-231.	0.7	26
11	Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. <i>Clinical Cancer Research</i> , 2020, 26, 6559-6567.	3.2	17
12	Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. <i>Blood</i> , 2020, 136, 823-830.	0.6	85
13	Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 13-13.	0.6	16
14	Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 4160-4160.	0.6	0
15	Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE/AIO KKR0306 trial. <i>International Journal of Cancer</i> , 2018, 142, 1047-1055.	2.3	12
16	Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE (AIOKKR0306). <i>International Journal of Cancer</i> , 2017, 140, 1918-1925.	2.3	15
17	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2017, 130, 721-721.	0.6	20
18	Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKKR0306). <i>Oncotarget</i> , 2017, 8, 105749-105760.	0.8	41

#	ARTICLE	IF	CITATIONS
19	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 1426-1434.	5.1	336
20	Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol. <i>Blood</i> , 2016, 128, 5692-5692.	0.6	0
21	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology, The</i> , 2015, 16, 1691-1699.	5.1	347
22	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3718-3726.	0.8	112
23	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1065-1075.	5.1	1,479
24	Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL). <i>Blood</i> , 2014, 124, 946-946.	0.6	4
25	Regulation of fas/fas ligand-mediated apoptosis by nuclear factor of activated T cells in megakaryocytes. <i>British Journal of Haematology</i> , 2012, 156, 523-534.	1.2	14
26	Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1-17.	2.0	311
27	Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. <i>Haematologica</i> , 2011, 96, 1568-1570.	1.7	67
28	Prophylactic transfer of BCR-ABL ⁻ , PR1 ⁻ , and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 7174-7184.	0.6	48
29	Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. <i>Haematologica</i> , 2011, 96, 1580-1588.	1.7	19
30	Lack of the Transcription Factor NFAT (Nuclear Factor of Activated T cells) c2 in Hematopoietic Progenitor Cells Results in Profound Hematological Abnormalities in Mice. <i>Blood</i> , 2011, 118, 1296-1296.	0.6	0
31	¹⁸⁸ Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and <i>in vivo</i> T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2010, 148, 910-917.	1.2	21
32	Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1611-1628.	2.0	226
33	Minimal Residual Disease (MRD) Based Preemptive 5-Azacitidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogeneic HSCT – Results of the RELAZA Trial. <i>Blood</i> , 2010, 116, 679-679.	0.6	41
34	Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of Activated T cells in megakaryocytes. <i>British Journal of Haematology</i> , 2009, 144, 395-408.	1.2	14
35	Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. <i>Leukemia Research</i> , 2009, 33, e215-e217.	0.4	14
36	Monitoring of donor chimerism in sorted CD34 ⁺ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2009, 94, 1613-1617.	1.7	98

#	ARTICLE	IF	CITATIONS
37	Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).. Blood, 2009, 114, 131-131.	0.6	27
38	Flow Cytometric Detection of Minimal Residual Disease One Year Post Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with B-CLL.. Blood, 2009, 114, 202-202.	0.6	2
39	Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 3351-3351.	0.6	2
40	Regulation of Fas/Fas Ligand-Mediated Apoptosis in Megakaryocytes by Nuclear Factor of Activated T Cells.. Blood, 2009, 114, 4023-4023.	0.6	0
41	Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. Clinical Cancer Research, 2008, 14, 5585-5593.	3.2	26
42	5-azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation.. Blood, 2008, 112, 2143-2143.	0.6	3
43	Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial. Blood, 2008, 112, 340-340.	0.6	1
44	Graft Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy Results of the EVTAC Trial. Blood, 2008, 112, 1172-1172.	0.6	1
45	Osteomyelosclerosis, Anemia and Extramedullary Hematopoiesis in Mice Deficient for the Transcription Factor NFAT (Nuclear Factor of Activated T Cells) c2. Blood, 2008, 112, 3726-3726.	0.6	0
46	Cidofovir and Foscarnet for Treatment of Human Herpesvirus 6 Encephalitis in a Neutropenic Stem Cell Transplant Recipient. Clinical Infectious Diseases, 2007, 44, e118-e120.	2.9	46
47	Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells: regulation of Fas ligand gene expression in megakaryocytes. Experimental Hematology, 2007, 35, 757-770.	0.2	26
48	The Calcineurin/NFAT Signaling Pathway Is a Target for the Collagen Type I-Induced Calcium Response in Megakaryocytes and Mediates Expression of Megakaryocytic Genes.. Blood, 2007, 110, 3647-3647.	0.6	0
49	Reciprocal Regulation of DSCR1 (Down Syndrome Critical Region 1) Expression and NFAT (Nuclear) Tj ETQq1 1 0.784314 rgBT /Overl	0.6	0
50	Graft Versus Host Disease Prophylaxis with Everolimus and Tacrolimus in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2006, 108, 2886-2886.	0.6	1
51	The Campath-Level at the Day of Transplant Predicts T-Cell Engraftment after Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 2951-2951.	0.6	0
52	Nuclear Factor of Activated T Cells Regulates Down Syndrome Critical Region 1 Gene Expression in Megakaryocytes.. Blood, 2006, 108, 1193-1193.	0.6	0
53	Specific Regulation of NFAT (Nuclear Factors of Activated T Cells) Expression in CD34+ Cells Differentiating into Diverse Hematopoietic Lineages.. Blood, 2006, 108, 4213-4213.	0.6	0
54	T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunology, Immunotherapy, 2005, 54, 1043-1058.	2.0	28

#	ARTICLE	IF	CITATIONS
55	Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+cells: down-regulation upon myeloid differentiation. <i>Journal of Leukocyte Biology</i> , 2004, 76, 1057-1065.	1.5	43
56	Reduced-Intensity Conditioning (RIC) with Busulfan, Fludarabine and Campath-1H Is Complicated by a High Rate of Graft Failure and Severe Viral Complications in Patients with CLL. <i>Blood</i> , 2004, 104, 5080-5080.	0.6	2
57	Midazolam: Significant Pain Reduction in Patients Undergoing Bone Marrow Puncture - a Clinical Trial. <i>Blood</i> , 2004, 104, 90-90.	0.6	2
58	Gemtuzumab Ozogamicin (Mylotarg®) as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2004, 104, 1245-1245.	0.6	0
59	Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 266-270.	1.1	46
60	Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. <i>Haematologica</i> , 2003, 88, 754-61.	1.7	13
61	Regulation of interferon- γ gene expression by nuclear factor of activated T cells. <i>Blood</i> , 2001, 98, 1480-1488.	0.6	116
62	Manipulating Immune Responses with Immunosuppressive Agents that Target NFAT. <i>Immunity</i> , 2000, 12, 359-372.	6.6	267
63	Down-Regulation of IL-4 Gene Transcription and Control of Th2 Cell Differentiation by a Mechanism Involving NFAT1. <i>Immunity</i> , 1997, 7, 849-860.	6.6	161
64	Interference of Ha-ras with inositol trisphosphate-mediated Ca ²⁺ -release. <i>FEBS Letters</i> , 1991, 291, 113-116.	1.3	5